Health Trials

About this trial

This study assesses how blood cell growth patterns (clonal hematopoiesis) relate to heart health or cardiovascular disease (CVD) after treatment in patients with Hodgkin lymphoma. In some patients, cancer treatment at a young age may lead to later complications, including problems with heart health. Checking for blood cell growth patterns called therapy-related clonal hematopoiesis (t-CH) can help predict who might be at risk for heart health problems after Hodgkin lymphoma treatment. If doctors know who may be at greater risk for developing later heart complications, then they can more closely monitor those patients to prevent or detect heart complications early.

Eligibility criteria

Qualifiers

Patient must be >= 7 years of age at the time of enrollment (age to perform an MRI without sedation).

History of pathologically confirmed classical Hodgkin Lymphoma (cHL) initially diagnosed when the patient was >= 2 and < 22 years of age.

As part of frontline therapy for cHL, the patient must have received a cumulative doxorubicin equivalent anthracycline dose of ≥ 200 mg/m² as estimated in doxorubicin isotoxic equivalents dose conversion calculation.

Note: History of COG therapeutic trial participation is not required. Institutional records (e.g., clinic note, treatment summary, chemotherapy roadmap) can be used as reference documentation of receipt of anthracycline dose.

Disqualifiers

Medical contraindication to undergoing a non-contrast cardiac MRI.

Patients with nodular lymphocyte-predominant HL.

Received cancer therapy in addition to that for primary Hodgkin Disease (e.g., for disease progression or recurrence, or subsequent malignant neoplasm).

History of CTCAE grade 3 or higher cardiovascular disease or condition known to exist prior to the patient's initial diagnosis of cHL.

Trial design

Treatments tested in this trial

  • Archive Sample Retrieval
  • Biospecimen Collection
  • Electronic Health Record Review
  • Magnetic Resonance Imaging
  • Survey Administration

Treatment groups

190 Participants
are divided into 1 treatment group

Locations

32
Canada
Hospital for Sick ChildrenM5G 1X8, TorontoOntario, Canada
United States
Alabama
USA Health Strada Patient Care Center36604, Mobile United States
Arizona
Phoenix Childrens Hospital85016, Phoenix United States
California
City of Hope Comprehensive Cancer Center91010, Duarte United States

Sponsors and collaborators

Children's Oncology Group

Lead sponsor

Source ClinicalTrials.gov